| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5594297 | American Heart Journal | 2017 | 30 Pages |
Abstract
Renal impairment is associated with increased rates of adverse events in STEMI patients treated with fibrinolysis. However, the safety and efficacy of pharmacoinvasive strategy are preserved in patients with renal impairment on presentation.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Juan J. MD, Shaun G. MD, MSc, Warren J. MD, Dennis T. MD, MSc, Akshay MD, MHS, Mary K. MSc, Carlo MD, Sigrun MD, PhD, Michel MD, Francisco MD, PhD, Bruno MD, Paul W. MD, Francesco MD, PhD, Federico MD, Pedro L. MD, Andrew T. MD,